Financial Performance - The net profit attributable to shareholders is expected to be between ¥205 million and ¥240 million, representing a decrease of 55.01% to 47.33% compared to the previous year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between ¥85 million and ¥120 million, reflecting a decline of 77.37% to 68.05% year-on-year[3]. Market Demand and Competition - The decline in performance is primarily due to decreased market demand for gluconate series raw materials and increased competition, leading to lower gross margins[4]. - The market demand for vitamin and cold medicine products is expected to weaken in 2024, resulting in decreased sales and prices for related products[4]. - The high revenue from trade pharmaceuticals in 2023 has led to increased inventory, but reduced market demand in 2024 has caused some products to become unsold, further impacting gross margins[4]. Financial Reporting - The financial data presented is preliminary and has not been audited by an accounting firm, with final figures to be disclosed in the 2024 annual report[5].
新赣江(873167) - 2024 Q4 - 年度业绩预告